Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Monday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to be announcing its Q3 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $1.92 million for the quarter.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Wednesday, May 14th. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.19). On average, analysts expect Citius Pharmaceuticals to post $-5 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Citius Pharmaceuticals Stock Down 4.7%

Shares of NASDAQ CTXR opened at $1.23 on Friday. Citius Pharmaceuticals has a fifty-two week low of $0.65 and a fifty-two week high of $23.22. The company has a 50 day simple moving average of $1.38 and a two-hundred day simple moving average of $1.45.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Maxim Group downgraded shares of Citius Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Citigroup downgraded shares of Citius Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 23rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Citius Pharmaceuticals in a research note on Monday, June 30th.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.